Drug Type Monoclonal antibody |
Synonyms GT 103, GT103 |
Target |
Action inhibitors |
Mechanism CFH inhibitors(Complement factor H inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Non-Small Cell Lung Cancer | Phase 1 | United States | 09 Jun 2020 |
Phase 2 | 21 | cgtdpmlwyg(wxwmzpxafc) = 1 patient experienced grade 3 lymphocyte decrease ubnyjizsnj (qurimtbvun ) View more | Positive | 05 Nov 2024 | |||
NCT04314089 (ASCO2024) Manual | Phase 1 | Advanced Lung Non-Small Cell Carcinoma PD-L1 Expression | KRAS Mutation | EGFR Mutation | 31 | GT103 10mg/kg IV every 3 weeks | xsmtlrlpsh(pqaguezori) = not reached nawdzbhtrb (cxqvmytugg ) Not Met View more | Positive | 24 May 2024 |
(PD-L1 positive (TPS > 1%)) | |||||||
Phase 1 | 25 | hlajqmojgo(ketvxgwncb) = rnihkifthq nvxtaqreeb (ghvzfhytsp ) | Positive | 26 May 2023 | |||
Phase 1 | 21 | rxyvhfvtou(ikfrnwqlie) = weeuyaflpr uqmniufgjh (enjibnjdqt, 40 - NE) View more | Positive | 01 Nov 2022 |